June 2020, Drugs Monitor

(29 June 2020) Baricitinib- induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia

June 30, 2020

Baricitinib restrains the immune dysregulation in COVID-19 patients https://doi.org/10.1101/2020.06.26.20135319 Evidences that baricitinib-induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia are provided in this study. A significant reduction in serum levels… Continue reading "(29 June 2020) Baricitinib- induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia"

(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19

June 30, 2020

Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials https://doi.org/10.1101/2020.06.22.20136531 This study is registered at INPLASY (INPLASY202060046). PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for… Continue reading "(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19"

(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm

June 29, 2020

Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia https://doi.org/10.1016/j.jinf.2020.06.052 113 patients were in the baricitinib-arm, and 78 in the control-arm. The results indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared… Continue reading "(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm"

(28 June 2020) Remdesivir- exhibits favorable safety and PK profiles

June 29, 2020

Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12840 This report describes two phase 1 studies that evaluated the safety and pharmacokinetics (PK) of single escalating and multiple intravenous (IV) doses of RDV… Continue reading "(28 June 2020) Remdesivir- exhibits favorable safety and PK profiles"

(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC

June 27, 2020

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https://doi.org/10.1101/2020.06.22.20133413 This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital… Continue reading "(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC"

(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals

June 25, 2020

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals https://doi.org/10.3389/fpubh.2020.00249 A total of 164 subjects were included in this study, 82 cases in the infected group and 82 controls in the uninfected group, with a median age of 37 years,… Continue reading "(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals"

(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality

June 25, 2020

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia https://academic.oup.com/cid/articleabstract/doi/10.1093/cid/ciaa812/5861638 In a single-center observational study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre-… Continue reading "(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality"

(23 June 2020) Tocilizumab- associated with lower mortality, when intubated patients were excluded

June 24, 2020

Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab – A Case- Controlled Study https://doi.org/10.1093/qjmed/hcaa206 We conducted a in patients with disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary… Continue reading "(23 June 2020) Tocilizumab- associated with lower mortality, when intubated patients were excluded"

(23 June 2020) Tocilizumab- ward based tocilizumab group showed better responses and less infections than ICU tocilizumab group

June 24, 2020

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care https://www.sciencedirect.com/science/article/pii/S1386653220301864?via%3Dihub In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62% of… Continue reading "(23 June 2020) Tocilizumab- ward based tocilizumab group showed better responses and less infections than ICU tocilizumab group"

(23 June 2020) Chloroquine and Hydroxychloroquine- time to reach viral RNA negativity significantly faster in moderate COVID-19 cases

June 23, 2020

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study https://doi.org/10.1101/2020.06.19.20136093 The clinical utility of chloroquine and hydroxychloroquine in treating COVID-19 was evaluated (ChiCTR2000030054). Forty-eight patients with moderate COVID-19 were randomized to… Continue reading "(23 June 2020) Chloroquine and Hydroxychloroquine- time to reach viral RNA negativity significantly faster in moderate COVID-19 cases"

Month: June 2020